Stem Cell Clinic

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

By Global News Feed

MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 18, 2024, and the company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “PBLA.” The CUSIP number for the common stock following the reverse stock split will be 69833W404.

Read more:
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

By Global News Feed

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.

Follow this link:
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

By Global News Feed

Project reflects Scorpius’ versatility through its multi-functional biologics facility and expertise in microbial fermentation Project reflects Scorpius’ versatility through its multi-functional biologics facility and expertise in microbial fermentation

View post:
NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

Pressure BioSciences’ New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million…

By Global News Feed

Uncle Bud’s, PBIO’s New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World’s Largest Retailers Uncle Bud’s, PBIO’s New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World’s Largest Retailers

Read more from the original source:
Pressure BioSciences’ New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million...

Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher…

By Global News Feed

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced two key executive team promotions. Paratek promoted Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer.

View post:
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher...

Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS

By Global News Feed

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.

See the original post here:
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS

SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024

By Global News Feed

- Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System - - Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System -

Here is the original post:
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024

→←